# Sunshine Lake Pharma Co., Ltd.: Phase 1 study withdrawn (Esophageal Cancer, Advanced Solid Tumor)

**Score:** 45/100

| Field | Value |
|---|---|
| Sponsor | Sunshine Lake Pharma Co., Ltd. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Pharmacokinetics Study of Larotinib in Subjects With Impaired Hepatic Function |
| NCT ID | NCT05048368 |
| Phase | Phase 1 |
| Status | withdrawn |
| Conditions | Esophageal Cancer; Advanced Solid Tumor |
| Intervention types | drug |
| Site countries | China |
| Posted | 2021-09-17 |
| Planned start | 2026-10-30 |
| Event | Withdrawn before enrolling |
| Event date | 2026-09-28 |
| Last update posted | 2026-09-28 |

## Why this score
- Industry sponsor (buys outsourced services).
- Stopped early: budget and sites freed up.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT05048368). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.